Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00809965 · ClinicalTrials.gov registry record · Phase 3
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
A Phase 3 study of Myocardial Infarction and Acute Coronary Syndrome, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 3
- Development phase
- 15,526
- Enrollment target
- 20
- Study locations
NCT00809965: Completed Phase 3 study of Myocardial Infarction and Acute Coronary Syndrome, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
NCT00809965 is a Phase 3 study of Myocardial Infarction and Acute Coronary Syndrome that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 15,526 participants, above the 4,439-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (250% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00809965, a Phase 3 study of Myocardial Infarction and Acute Coronary Syndrome, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 15,526 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary syndrome compared with placebo.
Primary Outcome
The percentage of patients with the first occurrence of the composite of death, myocardial infarction, or stroke. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Standard of care
- DRUG Rivaroxaban 2.5 mg
- DRUG Rivaroxaban 5 mg
Study Locations (20)
Florida
- - Jacksonville
- - Jupiter
- - Kissimmee
- - Miami
- - Ocala
- - Orlando
- - Ormond Beach
- - St. Petersburg
California
- - Anaheim
- - Burbank
- - Los Angeles
- - Mission Hills
- - San Diego
Alabama
- - Birmingham
- - Geneva
- - Mobile
Colorado
- - Aurora
- - Littleton
Georgia
- - Columbus
- - Rome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15,526 participants |
| Start Date | 2008-11 |
| Est. Completion | 2011-09 |
| Phase | Phase 3 |
What the finished NCT00809965 record still lists
NCT00809965 is an interventional study that assigns participants to a tested intervention. Its 15,526 participants enrollment target places it among the larger protocols in the corpus, above the 4,439-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (250% higher).
The record links to 4 conditions, with Myocardial Infarction appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT00809965 names 20 study sites across 5 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT00809965 about?
NCT00809965 is a clinical study titled "An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome". The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary syndrome compared with placebo.
What is the current status of trial NCT00809965?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 15,526 participants. The study started on 2008-11. Estimated completion is 2011-09.
What conditions does trial NCT00809965 study?
This clinical trial studies the following conditions: Myocardial Infarction, Acute Coronary Syndrome, Myocardial Ischemia, Unstable Angina.
What interventions are being tested in trial NCT00809965?
The interventions under investigation include: Placebo (DRUG), Standard of care (DRUG), Rivaroxaban 2.5 mg (DRUG), Rivaroxaban 5 mg (DRUG).
Who is sponsoring clinical trial NCT00809965?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00809965 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myocardial Infarction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00809965's enrollment target sits among peer trials
15,526 2nd of 64 the highest of 64 other Myocardial Infarction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myocardial Infarction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging
COMPLETED · Phase 3
-
Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction
COMPLETED · Phase 3
-
Occluded Artery Trial (OAT)
COMPLETED · Phase 3
-
IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.
COMPLETED · Phase 3
-
Myocardial Ischemia and Transfusion Pilot
COMPLETED · Phase 3
-
Vitamin Therapy for Prevention of Stroke
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05447806 · 15,732 participants · NA
Diabetes Clinical Decision Support
- NCT07000357 · 15,100 participants · Phase 3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
- NCT01737528 · 16,000 participants
STS/ACC Transcatheter Valve Therapy Registry (TVT Registry)
- NCT06380114 · 16,000 participants · NA
Stand Up 2 HPV: Standing Orders to Improve HPV Vaccination
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia